# FOLFIRINOX + NIS793 in Pancreatic Cancer

> **NCT05417386** · PHASE1 · TERMINATED · sponsor: **Colin D. Weekes, M.D., PhD** · enrollment: 4 (actual)

## Conditions studied

- Pancreas Cancer
- Metastatic Pancreatic Cancer
- Metastatic Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** FOLFIRINOX
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** NIS793
- **RADIATION:** Chemoradiation
- **DRUG:** Capecitabine
- **RADIATION:** Radiation Therapy
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT05417386
- **Lead sponsor:** Colin D. Weekes, M.D., PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-09
- **Primary completion:** 2023-07-10
- **Final completion:** 2023-07-10
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** NIS793 is no longer being developed
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05417386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05417386, "FOLFIRINOX + NIS793 in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05417386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*